TREE NEWS reports: Sanofi is considering an acquisition of US drugmaker Insmed and has hired advisers to assess the deal, which would be one of the largest biopharma M&A transactions in recent years. Insmed shares have fallen about 40% over the past 12 months, leaving it with a market value of roughly $26.6 billion. Sanofi’s shares are down 2.4% over the same period, giving the Paris-based group a market capitalization of €101.3 billion ($111.3 billion).
Sanofi weighs acquisition of US drugmaker Insmed
Sanofi exploring a deal for Insmed signals large-cap pharma's appetite for external growth is intact even as both stocks have lagged, and the disclosed adviser mandate suggests this is more than casual interest. The read-through lands on biotech M&A generally: a depressed Insmed valuation gives a cash-rich buyer a cheaper entry point, which matters for mid-cap biotech holders watching for similar takeout interest. Whether talks advance to a firm offer, and how Sanofi's own shareholders react to the capital commitment, is the open question.
Generated by AI for reference only.
Share on WeChat
Open WeChat → Scan → then tap "…" to send to a chat or Moments.
Tap "…" in the top-right corner to send to a chat or share to Moments.